Stock market analyst Salil Sharma has maintained 'buy' rating on Ranbaxy stock with target of Rs 449.

According to analyst, the investors can buy the stock with stop loss of Rs 427.

Today, the stock opened at Rs 444 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 538 and a low of Rs 240 on BSE.

Current EPS & P/E ratio stood at 16.19 and 27.55 respectively.

Ranbaxy Labs may shut one of its largest global bulk drug production facilities situated at Mohali, and is sourcing few products produced at the plant from local drug manufacturers previous to the closedown. Although the country's biggest drug manufacturer has been eyeing to outsource manufacturing of some products, it decided to limit the policy to small markets. In its most recent yearly report, Ranbaxy stated that it will look to outsource either products or manufacturing capacities for its business, but in nations that are outside its top 20 markets. Ranbaxy Laboratories, on June 08, has introduced the generic edition of the world's biggest selling drug Pfizer's Lipitor in the South African market. Ranbaxy becomes the first generic pharmaceutics to roll out the anti-cholesterol drug in South Africa.